Journal Article

Plasma Nevirapine Levels and 24-Week Efficacy in HIV-Infected Patients Receiving Nevirapine-Based Highly Active Antiretroviral Therapy with or without Rifampicin

Weerawat Manosuthi, Somnuek Sungkanuparph, Ammarin Thakkinstian, Sasivimol Rattanasiri, Achara Chaovavanich, Wisit Prasithsirikul, Sirirat Likanonsakul and Kiat Ruxrungtham

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 43, issue 2, pages 253-255
Published in print July 2006 | ISSN: 1058-4838
Published online July 2006 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/505210
Plasma Nevirapine Levels and 24-Week Efficacy in HIV-Infected Patients Receiving Nevirapine-Based Highly Active Antiretroviral Therapy with or without Rifampicin

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Seventy human immunodeficiency virus (HIV)—infected patients receiving rifampicin and 70 HIV-infected patients not receiving rifampicin were enrolled to receive 400 mg of nevirapine-based highly active antiretroviral therapy per day. Mean plasma nevirapine levels at 8 and 12 weeks were lower in patients receiving rifampicin (P = .048). However, virological and immunological outcomes at 24 weeks were not different between the 2 groups (P > .05).

Journal Article.  2075 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.